Vivo Bio Tech Receives Upgraded Stock Call from MarketsMOJO, Showing Strong Financials and Positive Growth.

Nov 19 2024 06:46 PM IST
share
Share Via
Vivo Bio Tech, a microcap pharmaceutical company, has been upgraded to 'Hold' by MarketsMojo on November 19, 2024. This decision is based on the company's strong Return on Capital Employed and low Debt-Equity ratio. The stock is currently in a Mildly Bullish range and has shown improvement from a Mildly Bearish trend. With attractive valuations and strong growth potential, it is worth considering, but the weak long-term fundamental strength should also be taken into account.
Vivo Bio Tech, a microcap pharmaceutical company, has recently received an upgraded stock call from MarketsMOJO. The company's stock has been upgraded to 'Hold' on November 19, 2024.

The decision to upgrade the stock to 'Hold' is based on several factors. Firstly, Vivo Bio Tech has shown a strong Return on Capital Employed (ROCE) of 14.57%, which is the highest in the industry. Additionally, the company has a low Debt-Equity ratio of 0.97 times, indicating a healthy financial position.

Furthermore, Vivo Bio Tech has also shown growth in its Profit Before Tax (PBT) less Other Income (OI) by 24.9%, with a current value of Rs 1.24 crore. This positive trend in profits is a good sign for investors.

From a technical standpoint, the stock is currently in a Mildly Bullish range and has shown improvement from a Mildly Bearish trend on November 19, 2024. This is supported by factors such as MACD, Bollinger Band, and KST, which all indicate a bullish trend for the stock.

In terms of valuation, Vivo Bio Tech has a ROCE of 10.7, making it a very attractive investment opportunity with a 1 Enterprise value to Capital Employed. Additionally, the stock is currently trading at a discount compared to its average historical valuations, making it a good time to invest.

Over the past year, the stock has generated a return of 20.35%, while its profits have risen by 178.4%. This indicates a strong growth potential for the company, with a PEG ratio of 0.

It is worth noting that the majority shareholders of Vivo Bio Tech are non-institutional investors, which may indicate a lack of confidence from larger investors.

However, the company does have a weak long-term fundamental strength, with a -3.21% CAGR growth in Net Sales over the last 5 years. This may be a cause for concern for potential investors.

In conclusion, while Vivo Bio Tech has shown positive growth and strong financials, it is important to consider the weak long-term fundamental strength before making any investment decisions. The upgraded stock call to 'Hold' by MarketsMOJO suggests a cautious approach for investors.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News